Vaccines against HEV
are in development [95-99]. Two large placebo-controlled trials found that vaccination
was more than 96 percent effective in preventing infection in high-risk settings
Little information exists regarding the efficacy of pre- or post-exposure immune globulin
(IG) prophylaxis for the prevention of HEV . There is at present no proof that immune globulin, including lots produced in countries where HEV is endemic, confers protection against hepatitis
Travelers to endemic areas should engage in practices that may prevent infection, such as avoiding drinking water of unknown purity, uncooked shellfish, and uncooked fruits or vegetables.
Treatment of infection remains supportive. Case reports have suggested a benefit from ribavirin
, suggesting it might be an option for chronic HEV infection, but more data are needed